REFERENCES
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med. 1997;337:725–733.
- Ruiz NM. Clinical history of efavirenz. Int J Clin Pract SuppL 1999;103:3–7.
- Bartlett J, Demasi R, Quinn J, et al. Meta-analysis of effi-cacy of triple combination therapy in antiretroviral-naive HIV-infected adults. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 519.
- Murray JS, Elashoff MR, Lacono-Connors LC. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
- Riddler S, Kahn J, Martin G, et al. Durable HIV suppression and tolerability with efavirenz (ER)) + indinavir (IDV): Resuits at 132 weeks. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 513.
- Ruiz NM, Bessen LJ, Manion DJ, et al. Potential adverse experiences associated with efavirenz (EFV, SustivaTM) in adults. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31—February 4, 1999; Chicago, IL. Abstract 655.
- Tashima K, Stryker R, Staszeski S, et al. Lipid profiles and clinical lipodystrophy in Study 006 patients. In: Program and abstracts of the 39th Interscience Conference on Anti-microbial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 1304.
- Moyle G, Baldwin C, Dent N, et al. Maintenance of virologi-cal control, changes in clinical lipodystrophy and metabolic parameters in persons switching from PI to efavirenz therapy. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 2064.